Assetmark Inc. Lowers Holdings in Humana Inc. (NYSE:HUM)

Key Points

• Assetmark Inc. has reduced its holdings in Humana Inc. by 58.7%, now owning 4,998 shares valued at approximately $1.32 million.
• Other institutional investors, including Deutsche Bank AG and Janney Montgomery Scott LLC, have increased their positions, indicating strong interest in the company amidst modifications in holdings.
• Humana's latest quarterly earnings report showed a missed EPS estimate of $6.27 against expectations of $6.32, although revenue increased by 9.6% year-over-year to $32.39 billion.

Assetmark Inc. cut its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 58.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,998 shares of the insurance provider's stock after selling 7,116 shares during the quarter. Assetmark Inc.'s holdings in Humana were worth $1,323,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of HUM. Avantax Advisory Services Inc. lifted its stake in Humana by 31.7% in the first quarter. Avantax Advisory Services Inc. now owns 2,425 shares of the insurance provider's stock worth $642,000 after acquiring an additional 583 shares during the period. Tempus Wealth Planning LLC raised its holdings in shares of Humana by 70.7% in the 1st quarter. Tempus Wealth Planning LLC now owns 1,499 shares of the insurance provider's stock valued at $397,000 after purchasing an additional 621 shares in the last quarter. Machina Capital S.A.S. bought a new stake in shares of Humana in the 1st quarter valued at about $1,782,000. Pinnacle Associates Ltd. lifted its position in shares of Humana by 8.5% in the 1st quarter. Pinnacle Associates Ltd. now owns 1,361 shares of the insurance provider's stock worth $360,000 after purchasing an additional 107 shares during the period. Finally, Unison Advisors LLC bought a new position in shares of Humana during the first quarter valued at approximately $2,681,000. Institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of NYSE:HUM traded down $2.68 on Friday, hitting $247.19. 1,756,006 shares of the company were exchanged, compared to its average volume of 1,854,830. The firm has a market capitalization of $29.73 billion, a P/E ratio of 18.97, a price-to-earnings-growth ratio of 1.64 and a beta of 0.44. The company has a current ratio of 1.95, a quick ratio of 1.91 and a debt-to-equity ratio of 0.69. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $382.72. The stock's 50 day moving average price is $235.09 and its 200 day moving average price is $255.24.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The business's revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.96 EPS. Sell-side analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on HUM shares. Oppenheimer boosted their price objective on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research note on Thursday, May 1st. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 target price on shares of Humana in a research report on Thursday, May 1st. Wall Street Zen lowered Humana from a "buy" rating to a "hold" rating in a research report on Saturday. Raymond James Financial upgraded Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research note on Thursday, May 1st. Finally, Piper Sandler cut their target price on Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research note on Thursday. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $281.62.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.